Raquel Ruiz-García1, Alexander Vargas-Hernández2, Ivan K Chinn2, Laura S Angelo2, Tram N Cao3, Zeynep Coban-Akdemir4, Shalini N Jhangiani5, Qingchang Meng5, Lisa R Forbes2, Donna M Muzny5, Luis M Allende6, Mohammed S Ehlayel7, Richard A Gibbs4, James R Lupski8, Gulbu Uzel9, Jordan S Orange2, Emily M Mace10. 1. Center for Human Immunobiology, Texas Children's Hospital, Houston, Tex; Servicio de Immunología, Hospital Universitario 12 de Octubre, Madrid, Spain. 2. Center for Human Immunobiology, Texas Children's Hospital, Houston, Tex; Department of Pediatrics, Baylor College of Medicine, Houston, Tex. 3. Center for Human Immunobiology, Texas Children's Hospital, Houston, Tex. 4. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Tex; Human Genome Sequencing Center, Baylor College of Medicine, Houston, Tex. 5. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Tex. 6. Servicio de Immunología, Hospital Universitario 12 de Octubre, Madrid, Spain. 7. Department of Pediatrics, Section of Pediatric Allergy and Immunology, Hamad Medical Corporation, Doha, and Department of Pediatrics, Weill Cornell Medical College, Ar-Rayyan, Qatar. 8. Department of Pediatrics, Baylor College of Medicine, Houston, Tex; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Tex; Human Genome Sequencing Center, Baylor College of Medicine, Houston, Tex. 9. Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 10. Center for Human Immunobiology, Texas Children's Hospital, Houston, Tex; Department of Pediatrics, Baylor College of Medicine, Houston, Tex. Electronic address: mace@bcm.edu.
Abstract
BACKGROUND: Heterozygous gain-of-function mutations in PI3K110δ lead to lymphadenopathy, lymphoid hyperplasia, EBV and cytomegalovirus viremia, and sinopulmonary infections. OBJECTIVE: The known role of natural killer (NK) cell function in the control of EBV and cytomegalovirus prompted us to investigate the functional and phenotypic effects of PI3K110δ mutations on NK cell subsets and cytotoxic function. METHODS: Mutations in patients were identified by using whole-exome or targeted sequencing. We performed NK cell phenotyping and functional analysis of patients' cells using flow cytometry, standard Cr51 cytotoxicity assays, and quantitative confocal microscopy. RESULTS: PI3K110δ mutations led to an altered NK cell developmental phenotype and cytotoxic dysfunction. Impaired NK cell cytotoxicity was due to decreased conjugate formation with susceptible target cells and abrogated activation of cell machinery required for target cell killing. These defects were restored partially after initiation of treatment with rapamycin in 3 patients. CONCLUSION: We describe novel NK cell functional deficiency caused by PI3K110δ mutation, which is a likely contributor to the severe viremia observed in these patients. Rapamycin treatment partially restores NK cell function, providing a further rationale for its use in patients with this disease.
BACKGROUND: Heterozygous gain-of-function mutations in PI3K110δ lead to lymphadenopathy, lymphoid hyperplasia, EBV and cytomegalovirus viremia, and sinopulmonary infections. OBJECTIVE: The known role of natural killer (NK) cell function in the control of EBV and cytomegalovirus prompted us to investigate the functional and phenotypic effects of PI3K110δ mutations on NK cell subsets and cytotoxic function. METHODS: Mutations in patients were identified by using whole-exome or targeted sequencing. We performed NK cell phenotyping and functional analysis of patients' cells using flow cytometry, standard Cr51 cytotoxicity assays, and quantitative confocal microscopy. RESULTS: PI3K110δ mutations led to an altered NK cell developmental phenotype and cytotoxic dysfunction. Impaired NK cell cytotoxicitywas due to decreased conjugate formation with susceptible target cells and abrogated activation of cell machinery required for target cell killing. These defects were restored partially after initiation of treatment with rapamycin in 3 patients. CONCLUSION: We describe novel NK cell functional deficiency caused by PI3K110δ mutation, which is a likely contributor to the severe viremia observed in these patients. Rapamycin treatment partially restores NK cell function, providing a further rationale for its use in patients with this disease.
Authors: Kun Jiang; Bin Zhong; Danielle L Gilvary; Brian C Corliss; Eric Vivier; Elizabeth Hong-Geller; Sheng Wei; Julie Y Djeu Journal: J Immunol Date: 2002-04-01 Impact factor: 5.422
Authors: M Elgizouli; D M Lowe; C Speckmann; D Schubert; J Hülsdünker; Z Eskandarian; A Dudek; A Schmitt-Graeff; J Wanders; S F Jørgensen; B Fevang; U Salzer; A Nieters; S Burns; B Grimbacher Journal: Clin Exp Immunol Date: 2015-11-09 Impact factor: 4.330
Authors: Jordan S Orange; Scott R Brodeur; Ashish Jain; Francisco A Bonilla; Lynda C Schneider; Roberto Kretschmer; Samuel Nurko; Wendy L Rasmussen; Julia R Köhler; Stephen E Gellis; Betsy M Ferguson; Jack L Strominger; Jonathan Zonana; Narayanaswamy Ramesh; Zuhair K Ballas; Raif S Geha Journal: J Clin Invest Date: 2002-06 Impact factor: 14.808
Authors: Colin M Segovis; Renee A Schoon; Christopher J Dick; Lucas P Nacusi; Paul J Leibson; Daniel D Billadeau Journal: J Immunol Date: 2009-06-01 Impact factor: 5.422
Authors: Carrie L Lucas; Hye Sun Kuehn; Fang Zhao; Julie E Niemela; Elissa K Deenick; Umaimainthan Palendira; Danielle T Avery; Leen Moens; Jennifer L Cannons; Matthew Biancalana; Jennifer Stoddard; Weiming Ouyang; David M Frucht; V Koneti Rao; T Prescott Atkinson; Anahita Agharahimi; Ashleigh A Hussey; Les R Folio; Kenneth N Olivier; Thomas A Fleisher; Stefania Pittaluga; Steven M Holland; Jeffrey I Cohen; Joao B Oliveira; Stuart G Tangye; Pamela L Schwartzberg; Michael J Lenardo; Gulbu Uzel Journal: Nat Immunol Date: 2013-10-28 Impact factor: 25.606
Authors: Mary Ellen Conley; A Kerry Dobbs; Anita M Quintana; Amma Bosompem; Yong-Dong Wang; Elaine Coustan-Smith; Amber M Smith; Elena E Perez; Peter J Murray Journal: J Exp Med Date: 2012-02-20 Impact factor: 14.307
Authors: Katharina L Willmann; Stefanie Klaver; Figen Doğu; Elisangela Santos-Valente; Wojciech Garncarz; Ivan Bilic; Emily Mace; Elisabeth Salzer; Cecilia Domínguez Conde; Heiko Sic; Peter Májek; Pinaki P Banerjee; Gregory I Vladimer; Sule Haskoloğlu; Musa Gökalp Bolkent; Alphan Küpesiz; Antonio Condino-Neto; Jacques Colinge; Giulio Superti-Furga; Winfried F Pickl; Menno C van Zelm; Hermann Eibel; Jordan S Orange; Aydan Ikincioğulları; Kaan Boztuğ Journal: Nat Commun Date: 2014-11-19 Impact factor: 14.919
Authors: Mohammad K Eldomery; Zeynep Coban-Akdemir; Tamar Harel; Jill A Rosenfeld; Tomasz Gambin; Asbjørg Stray-Pedersen; Sébastien Küry; Sandra Mercier; Davor Lessel; Jonas Denecke; Wojciech Wiszniewski; Samantha Penney; Pengfei Liu; Weimin Bi; Seema R Lalani; Christian P Schaaf; Michael F Wangler; Carlos A Bacino; Richard Alan Lewis; Lorraine Potocki; Brett H Graham; John W Belmont; Fernando Scaglia; Jordan S Orange; Shalini N Jhangiani; Theodore Chiang; Harsha Doddapaneni; Jianhong Hu; Donna M Muzny; Fan Xia; Arthur L Beaudet; Eric Boerwinkle; Christine M Eng; Sharon E Plon; V Reid Sutton; Richard A Gibbs; Jennifer E Posey; Yaping Yang; James R Lupski Journal: Genome Med Date: 2017-03-21 Impact factor: 11.117
Authors: Stuart G Tangye; Julia Bier; Anthony Lau; Tina Nguyen; Gulbu Uzel; Elissa K Deenick Journal: J Clin Immunol Date: 2019-03-25 Impact factor: 8.317
Authors: Jennifer L Cannons; Silvia Preite; Senta M Kapnick; Gulbu Uzel; Pamela L Schwartzberg Journal: Front Immunol Date: 2018-08-02 Impact factor: 7.561
Authors: Ivan K Chinn; Zhihui Xie; Eunice C Chan; Bianca M Nagata; Alexey Koval; Wei-Sheng Chen; Fan Zhang; Sundar Ganesan; Diana N Hong; Motoshi Suzuki; Glenn Nardone; Ian N Moore; Vladimir L Katanaev; Andrea E Balazs; Chengyu Liu; James R Lupski; Jordan S Orange; Kirk M Druey Journal: Sci Signal Date: 2021-07-27 Impact factor: 9.517
Authors: Danielle T Avery; Alisa Kane; Tina Nguyen; Anthony Lau; Akira Nguyen; Helen Lenthall; Kathryn Payne; Wei Shi; Henry Brigden; Elise French; Julia Bier; Jana R Hermes; David Zahra; William A Sewell; Danyal Butt; Michael Elliott; Kaan Boztug; Isabelle Meyts; Sharon Choo; Peter Hsu; Melanie Wong; Lucinda J Berglund; Paul Gray; Michael O'Sullivan; Theresa Cole; Steven M Holland; Cindy S Ma; Christoph Burkhart; Lynn M Corcoran; Tri Giang Phan; Robert Brink; Gulbu Uzel; Elissa K Deenick; Stuart G Tangye Journal: J Exp Med Date: 2018-07-17 Impact factor: 14.307